Abstract 15792: Reprogramming of Fibroblasts into Induced Cardiac Progenitor Cells with the CRISPR-dCas9 System

Lin Jiang,Jialiang Liang,Wei Huang,Wenfeng Cai,Christian Paul,Yigang Wang

IF: 37.8

2016-01-01

Circulation

Abstract:Background and Objective: Currently available regenerative clinical therapies for myocardial infarction could benefit from additional resources of cardiac lineage cells. Although the CRISPR-dCas9 s...

What problem does this paper attempt to address?

Abstract 210: Reprogramming Mouse Fibroblasts Into Cardiac Progenitor Cells Using Crispr Technique Targeting Endogenic Genes

Yi-gang Wang,Lin Jiang,Jialiang Liang,Wei Huang,Christian Paul

DOI: https://doi.org/10.1161/res.127.suppl_1.210

IF: 23.213

2020-07-31

Circulation Research

Abstract:Background and Objective: CRISPR tools that allow for precise manipulation of individual loci have not been used in generation of i nduced c ardiac p rogenitor c ells ( iCPC s). This study was designed to determine the feasibility and effectiveness of reprogramming fibroblasts into iCPC using CRISPR activation (CRISPRa) system. Methods: Tail-tip fibroblasts (TTFs) were isolated from Nkx2-5 cardiac enhancer GFP reporter mice. A gRNA pool targeting 17 progenitor genes was synthesized and transduced with dCas9-VP64 lentivirus into TTFs ( Fig.1A ). The phenotype of iCPCs was then characterized by immunostaining and FACS of progenitor markers. Finally, the cardiac-lineage differentiation potential of iCPCs was determined by immunostaining and electrophysiological assay under defined induction mediums. Results: iCPCs with GFP expression were formed in TTFs after transduction of CRISPRa targeting Isl1, Gata4, Baf60c, Tbx5 and Nkx2-5 (Fig.1B), while GFP was not activated by control virus. Cardiac progenitor markers were activated in iCPCs as shown by immunostaining (Fig.1C). The generation efficiency of Flk1-postive iCPCs induced by CRISPRa was ~60% as showed by FACS. iCPCs can be differentiated into cardiomyocytes as identified by immunostaining of cardiac-specific markers (Fig.1D). The iCPC-derived cardiomyocytes displayed spontaneous beating and showed cardiac action potentials (Fig.1E). Conclusion: The CRISPRa system is an efficient and specific way to generate iCPCs, which could provide a novel source of cells for cardiac regenerative medicine. Conversion of fibroblasts into cardiac progenitors poses a novel therapeutic option for repair of myocardial infarction.

cardiac & cardiovascular systems,peripheral vascular disease,hematology
Abstract 15721: CRISPR Activates Heterochromatic Cardiac Genes in Fibroblasts to Initiate Lineage Conversion into Cardiac Progenitors

Suchandrima Dutta,Jialiang Liang,Wei Huang,Xingyu He,Christian Paul,Yi-gang Wang

DOI: https://doi.org/10.1161/circ.148.suppl_1.15721

IF: 37.8

2023-01-01

Circulation

Abstract:Introduction: Our previous studies have demonstrated that CRISPR activation (CRISPRa) of endogenous genes was sufficient to convert fibroblasts into induced cardiovascular progenitor cells (iCPCs) for myocardial regenerative therapy. However, reprogramming efficiency remains a challenge and little has been elucidated about the epigenetic mechanisms of cellular reprogramming, which will be important for methodological improvements or refinements. Hypothesis: CRISPRa complex can alter the chromatin accessibility and activity of heterochromatic cardiac genes in fibroblasts, directly initiating cardiac reprogramming. Methods: A fibroblast-specific CRISPRa mice model (Pdgfra-cre/ERT; ROSA-dCas9-SunTag) was generated. SgRNAs targeting the promoter region of Gata4, Isl1, Nkx2-5, Baf60c, or Tbx5 genes were transduced through an AAV system in cardiac fibroblast isolated from transgenic mice. iCPCs were confirmed via immunostaining of CPC markers and cardiac electrophysiological assays. iCPCs were collected for RNA-seq, ATAC-seq, and ChIP-seq after reprogramming induction to reveal the epigenetic landscape modulated by CRISPRa. Results: The CRISPRa system was activated in ~80% of fibroblasts after tamoxifen induction and AAV-sgRNA transfection. The reprogrammed iCPCs were characterized by immunostaining of proliferative markers (Ki67 and Pcna), progenitor surface markers (Flk1 and Ssea1), and markers of cardiac tri-lineage cells after induced differentiation. RNA-seq data showed the upregulation of genes associated with cell cycling (Cdkn1b, Aurkb, etc.) and heart development (Myh6, Irx4, etc.) in CRISPRa-induced cells. ATAC-seq showed increased chromatin accessibility at the loci of cardiogenic genes targeted by CRISPRa in fibroblasts. Furthermore, ChIP-seq of Gata4, Nkx2.5, and Tbx5 associated DNA shows that these factors can bind to their own promoter regions in fibroblasts after CRISPRa induction. Conclusions: CRISPRa complexes open the chromatin of the targeted genes in fibroblasts and establish an endogenous autoregulatory loop to ensure stable reprogramming into cardiac progenitors.
In Vivo Reprogramming of Mouse Fibroblasts into Cardiac Progenitor Cells for Myocardial Infarction Treatment

Jialiang Liang,Yi-gang Wang

DOI: https://doi.org/10.1161/circ.146.suppl_1.13281

IF: 37.8

2022-01-01

Circulation

Abstract:Introduction: Our previous study demonstrated that fibroblasts can be reprogrammed into induced cardiovascular progenitor cells (iCPCs) by a CRISPR activation approach. However, it is still unknown whether in vivo iCPC reprogramming can be achieved by direct activation of endogenous genes. Hypothesis: Direct activation of endogenous loci by using CRISPR tools targeting genomic DNA can fulfill in vivo iCPC reprogramming to repair infarcted hearts. Methods: A new fibroblast-specific CRISPRa model (Col1a2-cre/ERT;CAG-cas9) was generated. SgRNAs targeting the core promoter region of Gata4, Isl1, Nkx2-5, Baf60c, or Tbx5 were locally introduced through an AAV system in MI mice that were created by permanent LAD ligation. Heart function was measured by echocardiography and tissue sections were harvested for immunostaining. Cardiovascular cells derived from iCPCs were determined by immunostaining, ex vivo characterization, and electrophysiological assay. Results: The CRISPR system was activated in ~50% of fibroblasts after tamoxifen induction. The lineage conversion into iCPCs was identified by the Nkx2.5-eGFP reporter. eGFP+ cells were expressing proliferative markers (Ki67 and Pcna) and aggregated into spheres during suspension culture after sorting. Progenitor markers (Flk1, Ssea1, and Pdgf-α) were co-expressed in eGPF+ cells. The ejection fraction and scar formation of infarcted hearts were improved after injection of sgRNA-AAVs for 4 weeks. The engrafted iCPCs were identified by the lineage-tracing reporter and differentiated into cTnT+ cardiomyocytes, α-SMA+ smooth muscle cells, or CD31+ endothelial cells in infarcted hearts. Conclusions: Activation of endogenous loci enables in vivo iCPC reprogramming for cardiac regenerative medicine.
Direct Reprogramming of Fibroblasts into Cardiomyocytes

Yueqiu Chen,Ziying Yang,Zhen-Ao Zhao,Zhenya Shen

DOI: https://doi.org/10.1186/s13287-017-0569-3

2017-01-01

Stem Cell Research & Therapy

Abstract:Cardiovascular diseases are the leading causes of death in the world. The limited regenerative capacity of adult cardiomyocytes is the major barrier for heart regeneration. After myocardial infarction, myofibroblasts are the dominant cell type in the infarct zone. Therefore, it is a good idea to reprogram terminally differentiated myofibroblasts into cardiomyocyte-like cells directly, providing a good strategy to simultaneously reduce scar tissue and increase functional cardiomyocytes. Transcription factors were first identified to reprogram myofibroblasts into cardiomyocytes. Thereafter, microRNAs and/or small molecules showed great potential to optimize the reprogramming process. Here, we systemically summarize and compare the major progress in directed cardiac reprogramming including transcription factors and miRNAs, especially the small molecules. Furthermore, we discuss the challenges needed to be overcome to apply this strategy clinically.
CRISPR activation of endogenous genes reprograms fibroblasts into cardiovascular progenitor cells for myocardial infarction therapy

Lin Jiang,Jialiang Liang,Wei Huang,Jianyong Ma,Ki Ho Park,Zhichao Wu,Peng Chen,Hua Zhu,Jian-Jie Ma,Wenfeng Cai,Christian Paul,Liang Niu,Guo-Chang Fan,Hong-Sheng Wang,Onur Kanisicak,Meifeng Xu,Yigang Wang

DOI: https://doi.org/10.1016/j.ymthe.2021.10.015

IF: 12.91

2022-01-01

Molecular Therapy

Abstract:Fibroblasts can be reprogrammed into cardiovascular progenitor cells (CPCs) using transgenic approaches, although the underlying mechanism remains unclear. We determined whether activation of endogenous genes such as Gata4, Nkx2.5, and Tbx5 can rapidly establish autoregulatory loops and initiate CPC generation in adult extracardiac fibroblasts using a CRISPR activation system. The induced fibroblasts (>80%) showed phenotypic changes as indicated by an Nkx2.5 cardiac enhancer reporter. The progenitor characteristics were confirmed by colony formation and expression of cardiovascular genes. Cardiac sphere induction segregated the early and late reprogrammed cells that can generate functional cardiomyocytes and vascular cells in vitro. Therefore, they were termed CRISPR-induced CPCs (ciCPCs). Transcriptomic analysis showed that cell cycle and heart development pathways were important to accelerate CPC formation during the early reprogramming stage. The CRISPR system opened the silenced chromatin locus, thereby allowing transcriptional factors to access their own promoters and eventually forming a positive feedback loop. The regenerative potential of ciCPCs was assessed after implantation in mouse myocardial infarction models. The engrafted ciCPCs differentiated into cardiovascular cells in vivo but also significantly improved contractile function and scar formation. In conclusion, multiplex gene activation was sufficient to drive CPC reprogramming, providing a new cell source for regenerative therapeutics.

genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
Direct Reprogramming of Cardiac Fibroblasts to Repair the Injured Heart

Emma Adams,Rachel McCloy,Ashley Jordan,Kaitlin Falconer,Iain M. Dykes

DOI: https://doi.org/10.3390/jcdd8070072

2021-06-22

Journal of Cardiovascular Development and Disease

Abstract:Coronary heart disease is a leading cause of mortality and morbidity. Those that survive acute myocardial infarction are at significant risk of subsequent heart failure due to fibrotic remodelling of the infarcted myocardium. By applying knowledge from the study of embryonic cardiovascular development, modern medicine offers hope for treatment of this condition through regeneration of the myocardium by direct reprogramming of fibrotic scar tissue. Here, we will review mechanisms of cell fate specification leading to the generation of cardiovascular cell types in the embryo and use this as a framework in which to understand direct reprogramming. Driving expression of a network of transcription factors, micro RNA or small molecule epigenetic modifiers can reverse epigenetic silencing, reverting differentiated cells to a state of induced pluripotency. The pluripotent state can be bypassed by direct reprogramming in which one differentiated cell type can be transdifferentiated into another. Transdifferentiating cardiac fibroblasts to cardiomyocytes requires a network of transcription factors similar to that observed in embryonic multipotent cardiac progenitors. There is some flexibility in the composition of this network. These studies raise the possibility that the failing heart could one day be regenerated by directly reprogramming cardiac fibroblasts within post-infarct scar tissue.

cardiac & cardiovascular systems
Reprogramming Fibroblasts Toward Cardiomyocytes, Neural Stem Cells and Hepatocytes by Cell Activation and Signaling-Directed Lineage Conversion

Saiyong Zhu,Haixia Wang,Sheng Ding

DOI: https://doi.org/10.1038/nprot.2015.059

IF: 14.8

2015-01-01

Nature Protocols

Abstract:common set of reprogramming factors is used to temporarily activate somatic cells into a transition state; these cells are subsequently directed to various cell types via lineage-specific signals, circumventing the need to establish a pluripotent state.
Direct Cardiac Reprogramming Via Combined CRISPRa-Mediated Endogenous Gata4 Activation and Exogenous Mef2c and Tbx5 Expression

Peisen Huang,Jun Xu,Benjamin Keepers,Yifang Xie,David Near,Yangxi Xu,James Rock Hua,Brian Spurlock,Shea Ricketts,Jiandong Liu,Li Wang,Li Qian

DOI: https://doi.org/10.1016/j.omtn.2024.102390

2024-01-01

Abstract:Direct cardiac reprogramming of fibroblasts into induced cardiomyocytes (iCMs) can be achieved by ectopic expression of cardiac transcription factors (TFs) via viral vectors. However, risks like genomic mutations, viral toxicity, and immune response, limited its clinical application. Trans-activation of endogenous TFs emerges as an alternative approach that may partially mitigate some of the risks. In this study, we utilized a modified CRISPRa/dCas9 strategy to transactivate endogenous reprogramming factors MEF2C, GATA4, TBX5 (M/G/T) to induce iCMs from both mouse and human fibroblasts. We identified single guide RNAs (sgRNAs) targeting promoters and enhancers of the TFs capable of activating various degrees of endogenous gene expression. CRISPRa-mediated Gata4 activation, combined with exogenous expression of Mef2c and Tbx5, successfully converted fibroblasts into iCMs. Despite extensive sgRNA screening, trans-activation of Mef2c and Tbx5 via CRISPRa remained less effective, potentially due to de novo epigenetic barriers. While future work and refined technologies are needed to determine whether cardiac reprogramming could be achieved solely through CRISPRa activation of endogenous factors, our findings provide proof of concept that reliance on exogenous TFs for reprogramming can be reduced through CRISPRa-mediated activation of endogenous factors, particularly Gata4, offering a novel strategy to convert scar-forming fibroblasts into iCMs for regenerative purposes.
In Vivo Lineage Reprogramming of Fibroblasts to Cardiomyocytes for Heart Regeneration

Li Wang,Jiandong Liu,Li Qian

DOI: https://doi.org/10.1007/978-3-319-65720-2_4

2017-01-01

Abstract:Heart disease remains a leading cause of death due to limited therapeutic regiments. Human and murine adult hearts suffer from limited regenerative capacity of cardiomyocytes after injury such as myocardial infarction. The advances of cellular reprogramming that leveraged knowledge from decades of research in developmental biology provide a promising approach to convert cell fate and generate reprogrammed cells in situ. Production of induced cardiomyocytes raises hopes for potential usage in regenerative medicine and disease modeling. Here we reviewed latest advances in reprogramming fibroblasts to cardiomyocyte-like cells and summarized the challenges that must be overcome to move this filed closer for clinic applications.
Abstract 15007: Chemical Enhancement of Direct Cardiac Reprogramming in Vitro and in Vivo

Tamer M Mohamed,Nicole R. Stone,Emily C. Berry,Ethan Radzinsky,Yü Huang,Karishma Pratt,Yen-Sin Ang,Pengzhi Yu,Haixia Wang,Shibing Tang,Sergey Magnitsky,Sheng Ding,Kathryn N. Ivey,Deepak Srivastava

IF: 37.8

2016-01-01

Circulation

Abstract:Reprogramming of cardiac fibroblasts into induced cardiomyocyte-like cells (iCMs) in situ represents a promising strategy for cardiac regeneration. A combination of three cardiac transcription fact...
Lineage Reprogramming Of Fibroblasts Into Expandable Cardiac Progenitor Cells By Defined Small Molecules

Jia Wang,Nan Cao

DOI: https://doi.org/10.1016/j.yjmcc.2019.11.124

IF: 5.763

2020-01-01

Journal of Molecular and Cellular Cardiology

Abstract:The existence of a resident cardiac stem cell population in adult mammalian hearts has been proved to be elusive. Thus, one of the major hurdle in cardiac cell therapy is the lack of a suitable cell type that can be safely and autologously generated from somatic cells, and allows for extensive expansion in vitro and robust cardiovascular differentiation in vivo. Here, we show that a cell population with extensive proliferation capacity and restricted cardiovascular differentiation potential can be generated by treating mouse fibroblasts with a combination of six compounds (6C) without foreign genetic materials. These chemically induced cardiovascular progenitor cells (ciCPCs) proliferated extensively for over 20 passages and could be expanded >1015-fold in chemically defined conditions. ciCPCs expressed cardiac signature genes and readily differentiated into functional cardiomyocytes (CMs), endothelial cells (ECs), and smooth muscle cells (SMCs) in vitro without the need of sequential induction with embryonic cardiogenic signals, even after long-term expansion. When transplanted into mouse hearts following myocardial infarction, ciCPCs spontaneously differentiated into CMs, ECs, and SMCs, and improved cardiac function for up to 12 weeks after transplantation. Epigenomic analyses revealed that 6C treatment in fibroblasts resulted in a rapid opening of previously closed chromatin in key cardiac developmental regulators, thus enabling the promoters/enhancers of these genes to bind effectors of major cardiogenic signals. This study provides a novel strategy free of foreign genetic material to generate cell sources that will not be compromised by growth arrest and may benefit ultimate individualized cardiac cell therapy.
Conversion of Human Fibroblasts into Functional Cardiomyocytes by Small Molecules

Nan Cao,Yu Huang,Jiashun Zheng,C. Ian Spencer,Yu Zhang,Ji-Dong Fu,Baoming Nie,Min Xie,Mingliang Zhang,Haixia Wang,Tianhua Ma,Tao Xu,Guilai Shi,Deepak Srivastava,Sheng Ding

DOI: https://doi.org/10.1126/science.aaf1502

IF: 56.9

2016-01-01

Science

Abstract:Reprogramming somatic fibroblasts into alternative lineages would provide a promising source of cells for regenerative therapy. However, transdifferentiating human cells into specific homogeneous, functional cell types is challenging. Here we show that cardiomyocyte-like cells can be generated by treating human fibroblasts with a combination of nine compounds that we term 9C. The chemically induced cardiomyocyte-like cells uniformly contracted and resembled human cardiomyocytes in their transcriptome, epigenetic, and electrophysiological properties. 9C treatment of human fibroblasts resulted in a more open-chromatin conformation at key heart developmental genes, enabling their promoters and enhancers to bind effectors of major cardiogenic signals. When transplanted into infarcted mouse hearts, 9C-treated fibroblasts were efficiently converted to chemically induced cardiomyocyte-like cells. This pharmacological approach to lineage-specific reprogramming may have many important therapeutic implications after further optimization to generate mature cardiac cells.
Another possible cell source for cardiac regenerative medicine: reprogramming adult fibroblasts to cardiomyocytes and endothelial progenitor cells.

Xinxing Xie,Aijun Sun,Zheyong Huang,Wenqing Zhu,Shijun Wang,Yunzeng Zou,Junbo Ge

DOI: https://doi.org/10.1016/j.mehy.2010.10.041

IF: 4.7

2011-01-01

Medical Hypotheses

Abstract:Ischemic heart disease (IHD) is a significant burden to healthcare systems in the world despite substantial advances in risk modification, pharmacological therapy and revascularization therapy. Stem cell therapy is emerging as a novel therapeutic paradigm for myocardial repair. Several cell types including embryonic stem cells, adult stem cells and induced pluripotent stem (iPS) cells have been used for the treatment of ischemic heart disease. But all these engrafted cells must be systematically or locally administered after being expanded in vitro, the rare differentiation into cardiomyocytes and low cellular survival of engrafted cells also limited the efficacy of stem cell therapy. Recent research indicated that it was feasible to reprogramme one mature cell type into another cell type directly by introducing several transcription factors, which was called transdifferentiation. We speculate that cell reprogramming might provide potential new cell sources for therapeutic cardiac regeneration. For these reasons, we hypothesize that converting cardiac fibroblasts to cardiomyocytes and endothelial progenitor cells (EPCs) either in vivo or in vitro might be a possible way for future therapeutic cardiac regeneration. Furthermore we also analyzed the possible difficulties we might face on way to realize this hypothesis.
Partial Cell Fate Transitions to Promote Cardiac Regeneration

Jianchang Yang

DOI: https://doi.org/10.3390/cells13232002

IF: 6

2024-12-05

Cells

Abstract:Heart disease, including myocardial infarction (MI), remains a leading cause of morbidity and mortality worldwide, necessitating the development of more effective regenerative therapies. Direct reprogramming of cardiomyocyte-like cells from resident fibroblasts offers a promising avenue for myocardial regeneration, but its efficiency and consistency in generating functional cardiomyocytes remain limited. Alternatively, reprogramming induced cardiac progenitor cells (iCPCs) could generate essential cardiac lineages, but existing methods often involve complex procedures. These limitations underscore the need for advanced mechanistic insights and refined reprogramming strategies to improve reparative outcomes in the heart. Partial cellular fate transitions, while still a relatively less well-defined area and primarily explored in longevity and neurobiology, hold remarkable promise for cardiac repair. It enables the reprogramming or rejuvenation of resident cardiac cells into a stem or progenitor-like state with enhanced cardiogenic potential, generating the reparative lineages necessary for comprehensive myocardial recovery while reducing safety risks. As an emerging strategy, partial cellular fate transitions play a pivotal role in reversing myocardial infarction damage and offer substantial potential for therapeutic innovation. This review will summarize current advances in these areas, including recent findings involving two transcription factors that critically regulate stemness and cardiogenesis. It will also explore considerations for further refining these approaches to enhance their therapeutic potential and safety.

cell biology
In situ reprogramming of cardiac fibroblasts into cardiomyocytes in mouse heart with chemicals

Zi-yang Chen,Si-jia Ji,Chen-wen Huang,Wan-zhi Tu,Xin-yue Ren,Ren Guo,Xin Xie

DOI: https://doi.org/10.1038/s41401-024-01308-6

IF: 7.169

2024-06-19

Acta Pharmacologica Sinica

Abstract:Cardiomyocytes are terminal differentiated cells and have limited ability to proliferate or regenerate. Condition like myocardial infarction causes massive death of cardiomyocytes and is the leading cause of death. Previous studies have demonstrated that cardiac fibroblasts can be induced to transdifferentiate into cardiomyocytes in vitro and in vivo by forced expression of cardiac transcription factors and microRNAs. Our previous study have demonstrated that full chemical cocktails could also induce fibroblast to cardiomyocyte transdifferentiation both in vitro and in vivo. With the development of tissue clearing techniques, it is possible to visualize the reprogramming at the whole-organ level. In this study, we investigated the effect of the chemical cocktail CRFVPTM in inducing in situ fibroblast to cardiomyocyte transdifferentiation with two strains of genetic tracing mice, and the reprogramming was observed at whole-heart level with CUBIC tissue clearing technique and 3D imaging. In addition, single-cell RNA sequencing (scRNA-seq) confirmed the generation of cardiomyocytes from cardiac fibroblasts which carries the tracing marker. Our study confirms the use of small molecule cocktails in inducing in situ fibroblast to cardiomyocyte reprogramming at the whole-heart level and proof-of-conceptly providing a new source of naturally incorporated cardiomyocytes to help heart regeneration.

pharmacology & pharmacy,chemistry, multidisciplinary
Direct Cardiac Reprogramming as a Novel Therapeutic Strategy for Treatment of Myocardial Infarction.

Hong Ma,Li Wang,Jiandong Liu,Li Qian

DOI: https://doi.org/10.1007/978-1-4939-6588-5_5

2017-01-01

Abstract:Direct reprogramming of fibroblasts into induced cardiomyocytes (iCMs) holds great promise as a novel therapy for the treatment of heart failure, a common and morbid disease that is usually caused by irreversible loss of functional cardiomyocytes (CMs). Recently, we and others showed that in a murine model of acute myocardial infarction, delivery of three transcription factors, Gata4, Mef2c, and Tbx5 converted endogenous cardiac fibroblasts into functional iCMs. These iCMs integrated electrically and mechanically with surrounding myocardium, resulting in a reduction in scar size and an improvement in heart function. Our findings suggest that iCM reprogramming may be a means of regenerating functional CMs in vivo for patients with heart disease. However, because relatively little is known about the factors that regulate iCM reprogramming, the applicability of iCM reprogramming is currently limited to the experimental settings in which it has been attempted. Specific hurdles include the relatively low conversion rate of iCMs and the need for reprogramming to occur in the context of acute injury. Therefore, before this treatment can become a viable therapy for human heart disease, the optimal condition for efficient iCM generation must be determined. Here, we provide a detailed protocol for both in vitro and in vivo iCM generation that has been optimized so far in our lab. We hope that this protocol will lay a foundation for future further improvement of iCM generation and provide a platform for mechanistic studies.
Direct cardiac reprogramming: Toward the era of multi-omics analysis.

Mengxin Liu,Jie Liu,Tong Zhang,Li Wang

DOI: https://doi.org/10.1016/j.cellin.2022.100058

2022-01-01

Cell Insight

Abstract:Limited regenerative capacity of adult cardiomyocytes precludes heart repair and regeneration after cardiac injury. Direct cardiac reprograming that converts scar-forming cardiac fibroblasts (CFs) into functional induced-cardiomyocytes (iCMs) offers promising potential to restore heart structure and heart function. Significant advances have been achieved in iCM reprogramming using genetic and epigenetic regulators, small molecules, and delivery strategies. Recent researches on the heterogeneity and reprogramming trajectories elucidated novel mechanisms of iCM reprogramming at single cell level. Here, we review recent progress in iCM reprogramming with a focus on multi-omics (transcriptomic, epigenomic and proteomic) researches to investigate the cellular and molecular machinery governing cell fate conversion. We also highlight the future potential using multi-omics approaches to dissect iCMs conversion for clinal applications.
Abstract 13767: Cardiac Reprogramming Reduces Fibrosis and Improves Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction

Yu Yamada,Taketaro Sadahiro,Koji Nakano,Seiichiro Honda,Yuto Abe,Ryo Fujita,Masaki Ieda

DOI: https://doi.org/10.1161/circ.148.suppl_1.13767

IF: 37.8

2023-11-07

Circulation

Abstract:Introduction: Heart failure with preserved ejection fraction (HFpEF) is a disease associated with high morbidity and mortality. Cardiac fibroblasts (CFs) contribute to HFpEF pathogenesis through interstitial/perivascular fibrosis and diastolic dysfunction; however, little is known regarding the mechanisms of the fibrosis, and therapies targeting it are lacking. Cardiac reprogramming is a promising approach for myocardial infarction by overexpressing Mef2c/Gata4/Tbx5/Hand2 (MGTH) in CFs, however, it remains undetermined whether cardiac reprogramming is effective in HFpEF. Aims: This study aims to determine the effectiveness of cardiac reprogramming in HFpEF. Methods: We generated a novel Tcf21iCre/Tomato/MGTH2A transgenic mouse system, where cardiac reprogramming can be induced in a druggable manner with lineage tracing. We first tested whether this system could improve the HFpEF mouse model. To determine the efficacy of cardiac reprogramming and the mechanisms of cardiac fibrosis in HFpEF, we performed multi-omics, including single cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and epigenome analysis. Finally, we generated mouse lines that induce each of the reprogramming factors and investigated whether overexpression of a single factor alone could improve HFpEF, which we also examined in human CF. Results: We found that cardiac reprogramming reduced fibrosis and improved diastolic dysfunction in HFpEF. scRNA-seq and spatial transcriptomics revealed that multiple CF clusters upregulated fibrotic profiles to induce diffuse interstitial fibrosis, whereas the distinct profibrotic CF cluster contributed to perivascular fibrosis, which were reversed with cardiac reprogramming. Mechanistically, cardiac reprogramming changed the epigenetic landscape by recruiting Gata4 to loci. Notably, overexpression of only Gata4 improved HFpEF by reducing fibrosis and suppressed profibrotic signatures in human CFs without generating cardiomyocytes. Conclusions: Cardiac reprogramming may be a promising approach for HFpEF via anti-fibrosis.

cardiac & cardiovascular systems,peripheral vascular disease
Advances in Cellular Reprogramming-Based Approaches for Heart Regenerative Repair

Xingyu He,Jialiang Liang,Christian Paul,Wei Huang,Suchandrima Dutta,Yigang Wang

DOI: https://doi.org/10.3390/cells11233914

IF: 6

2022-12-04

Cells

Abstract:Continuous loss of cardiomyocytes (CMs) is one of the fundamental characteristics of many heart diseases, which eventually can lead to heart failure. Due to the limited proliferation ability of human adult CMs, treatment efficacy has been limited in terms of fully repairing damaged hearts. It has been shown that cell lineage conversion can be achieved by using cell reprogramming approaches, including human induced pluripotent stem cells (hiPSCs), providing a promising therapeutic for regenerative heart medicine. Recent studies using advanced cellular reprogramming-based techniques have also contributed some new strategies for regenerative heart repair. In this review, hiPSC-derived cell therapeutic methods are introduced, and the clinical setting challenges (maturation, engraftment, immune response, scalability, and tumorigenicity), with potential solutions, are discussed. Inspired by the iPSC reprogramming, the approaches of direct cell lineage conversion are merging, such as induced cardiomyocyte-like cells (iCMs) and induced cardiac progenitor cells (iCPCs) derived from fibroblasts, without induction of pluripotency. The studies of cellular and molecular pathways also reveal that epigenetic resetting is the essential mechanism of reprogramming and lineage conversion. Therefore, CRISPR techniques that can be repurposed for genomic or epigenetic editing become attractive approaches for cellular reprogramming. In addition, viral and non-viral delivery strategies that are utilized to achieve CM reprogramming will be introduced, and the therapeutic effects of iCMs or iCPCs on myocardial infarction will be compared. After the improvement of reprogramming efficiency by developing new techniques, reprogrammed iCPCs or iCMs will provide an alternative to hiPSC-based approaches for regenerative heart therapies, heart disease modeling, and new drug screening.

cell biology
Optimization and Enrichment of Induced Cardiomyocytes Derived from Mouse Fibroblasts by Reprogramming with Cardiac Transcription Factors.

Jiaxin Tian,Rong Wang,Qian Hou,Meirong Li,Li Chen,Xiangdong Deng,Ziying Zhu,Yali Zhao,Wenjun He,Xiaobing Fu

DOI: https://doi.org/10.3892/mmr.2017.8285

IF: 3.423

2017-01-01

Molecular Medicine Reports

Abstract:Ischemic heart disease within developed countries has been associated with high rates of morbidity and mortality. Cell‑based cardiac repair is an emerging therapy for the treatment of cardiac diseases; however, a limited source of the optimal type of donor cell, such as an autologous cardiomyocyte, restricts clinical application. The novel therapeutic use of induced pluripotent stem cells (iPSCs) may serve as a unique and unlimited source of cardiomyocytes; however, iPSC contamination has been associated with teratoma formation following transplantation. The present study investigated whether cardiomyocytes from mouse fibroblasts may be reprogrammed in vitro with four cardiac transcription factors, including GATA binding protein 4, myocyte‑specific enhancer factor 2C, T‑box transcription factor 5, and heart‑ and neural crest derivatives‑expressed protein 2 (GMTH). Cardiac‑specific markers, including α‑myosin heavy chain (α‑MHC), β‑MHC, atrial natriuretic factor, NK2 homeobox 5 and cardiac troponin T were observed within mouse fibroblasts reprogrammed with GMTH, which was reported to be more effective than GMT. In addition, Percoll density centrifugation enriched a population of ~72.4±5.5% α‑MHC+ induced cardiomyocytes, which retained the expression profile of cardiomyocyte markers and were similar to natural neonatal cardiomyocytes in well‑defined sarcomeric structures. The findings of the present study provided a potential solution to myocardial repair via a cell therapy applying tissue engineering with minimized risks of immune rejection and tumor formation.

Abstract 15792: Reprogramming of Fibroblasts into Induced Cardiac Progenitor Cells with the CRISPR-dCas9 System

Abstract 210: Reprogramming Mouse Fibroblasts Into Cardiac Progenitor Cells Using Crispr Technique Targeting Endogenic Genes

Abstract 15721: CRISPR Activates Heterochromatic Cardiac Genes in Fibroblasts to Initiate Lineage Conversion into Cardiac Progenitors

In Vivo Reprogramming of Mouse Fibroblasts into Cardiac Progenitor Cells for Myocardial Infarction Treatment

Direct Reprogramming of Fibroblasts into Cardiomyocytes

CRISPR activation of endogenous genes reprograms fibroblasts into cardiovascular progenitor cells for myocardial infarction therapy

Direct Reprogramming of Cardiac Fibroblasts to Repair the Injured Heart

Reprogramming Fibroblasts Toward Cardiomyocytes, Neural Stem Cells and Hepatocytes by Cell Activation and Signaling-Directed Lineage Conversion

Direct Cardiac Reprogramming Via Combined CRISPRa-Mediated Endogenous Gata4 Activation and Exogenous Mef2c and Tbx5 Expression

In Vivo Lineage Reprogramming of Fibroblasts to Cardiomyocytes for Heart Regeneration

Abstract 15007: Chemical Enhancement of Direct Cardiac Reprogramming in Vitro and in Vivo

Lineage Reprogramming Of Fibroblasts Into Expandable Cardiac Progenitor Cells By Defined Small Molecules

Conversion of Human Fibroblasts into Functional Cardiomyocytes by Small Molecules

Another possible cell source for cardiac regenerative medicine: reprogramming adult fibroblasts to cardiomyocytes and endothelial progenitor cells.

Partial Cell Fate Transitions to Promote Cardiac Regeneration

In situ reprogramming of cardiac fibroblasts into cardiomyocytes in mouse heart with chemicals

Direct Cardiac Reprogramming as a Novel Therapeutic Strategy for Treatment of Myocardial Infarction.

Direct cardiac reprogramming: Toward the era of multi-omics analysis.

Abstract 13767: Cardiac Reprogramming Reduces Fibrosis and Improves Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction

Advances in Cellular Reprogramming-Based Approaches for Heart Regenerative Repair

Optimization and Enrichment of Induced Cardiomyocytes Derived from Mouse Fibroblasts by Reprogramming with Cardiac Transcription Factors.